Gene therapy using adenoviral vector containing the endostatin gene is a promising strategy for advanced cancers. However, host immune response to adenovirus and the lack of the requisite coxsackie-adenovirus receptor (CAR) in many primary cells limit the in vivo application. Liposome-complexed adenoviral vectors have proven to be useful for enhancing gene delivery in target cells that lack adenoviral receptors and avoiding a neutralizing antibody response. Here, we investigated antitumor effects of intravenous administration with PEG-PE cationic liposome-encapsulated recombinant human endostatin adenovirus (Ad-hEndo) on CAR-negative ovarian cancer. Electron micrography (EM) showed that these liposomes efficiently encapsulated the vectors, allowing CAR-independent adenovector transduction. The results showed that the complex enhanced transfection efficiency of recombinant adenovirus. Prolonged systemic administration was performed in immunocompetent mice and did not induce significant antibody response. The antitumor effect with PEG-PE cationic liposome encapsulated with Ad-hE (Ad-hE/lipo) was evaluated in the human ovarian cancer model. Systemic administration was well tolerated and resulted in marked suppression of tumor growth in an established ovarian cancer model, which was associated with a decreased number of micro-vessels and increased apoptosis of tumor cells. Our study shows that PEG-PE cationic liposome-encapsulated Ad-hE (Ad-hE/Lipo) can be administrated intravenously and lastingly to inhibit angiogenesis, thus showing promising clinical application.
Introduction
Ovarian cancer is the leading cause of death among the gynecological malignancies. Owing to the lack of specific symptoms or effective screening modalities, most patients present with late-stage disease. After surgical debulking of the primary tumor and ascites drainage, increased growth of metastatic nodules has been observed in ovarian cancer patients. Therefore, prognosis is poor, and the 5-year survival rate is approximately 40%. 1 Thus, it is imminent to seek new strategies.
Angiogenesis has a central role in the process of growth and metastasis of primary solid tumors. 2, 3 Ovarian cancer growth is angiogenesis dependent, and inhibition of neovascularization may therefore indirectly inhibit tumor cell growth and lead to tumor dormancy. 4 Endostatin, the C-terminal proteolytic fragment of collagen XVIII, is a potent endogenous vascular inhibitor. 5 Endostatin interferes with the angiogenic process through multiple ways but without a direct effect on the tumors: it interferes with VEGFR-2 and FGF-2-induced signal transduction, blocks endothelial cells motility, induces endothelial cells apoptosis and G1 arrest of endothelial cells through inhibition of cyclin D1, and blocks tumor necrosis factorinduced activation of proangiogenic gene expression. In addition, endostatin interacts with the heparan sulfate proteoglycans, glypican-1 and -4, and binds to a5b1 integrin on the cell surface. [6] [7] [8] Endostatin efficiently blocks angiogenesis, suppresses primary tumor growth and metastasis and induces dormancy in mice tumor models. Moreover, anti-angiogenic therapy with endostatin does not induce acquired drug resistance, and neither does it generate apparent toxicity. 5, 9 However, there are some obstacles in clinical application with endostatin owing to difficulties and the high cost of producing large quantities of biologically active proteins and the short half-life of endostatin. [10] [11] [12] Gene therapy based on the genes is thus preferable to solve these problems. A number of investigators have used virus gene therapy as one possible route to supplement ovarian cancer conventional chemotherapy. 13, 14 Adenoviral vectors have been widely used for gene therapy because they can transfect many cell types. [15] [16] [17] [18] [19] [20] [21] However, they are limited both by their innate immunogenicity and by their dependence on appropriate receptors expressed on target cells, such as Coxsackieadenovirus receptor (CAR), which result in decreased gene delivery efficiency and failure to repeated treatment of adenoviral drugs. [22] [23] [24] [25] Inspiringly, recent studies suggest that encapsulation of adenovirus with liposome may be an effective strategy to escape the neutralization caused by humoral immune response and to enhance gene transfer. [25] [26] [27] [28] [29] Developing a more efficient and safer gene delivery liposome system may also promote the potential of a recombined adenovirus-encoding human endostatin.
Here, we developed 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(poly-ethyleneglycol)]-2000 (PEG-PE) cationic liposome composed of Dioleoyltrimethylaminopropane (DOTAP), 1,2-dioleoyl-3-phosphatidylethanolamine and PEG-PE to encapsulate the recombined adenovirus-encoding human endostatin. We investigated the antitumor activities of the intravenous administration of PEG-PE cationic liposome-complexed recombinant human endostatin adenovirus in nude mice model. Our study indicates that the complex can not only be tolerated well by recipient mice, but also generate enhanced and lasting antitumor effects in vivo, and appears to be safe for further clinical application.
Materials and methods
Cell lines and animals SKOV-3 cell line and the human embryonic kidney (HEK293) were obtained from ATCC (American Type Culture Collection) (Manassas, VA), and cultured in RPMI-1640 (Gibco/Invitrogen, Carlsbad, CA) supplemented with 10% FBS (fetal bovine serum) plus ampicillin and streptomycin routinely in a 5% CO 2 incubator at 37 1C. Female nude mice (6-8 weeks old) were purchased from the Laboratory Animal Center of Sichuan University.
Recombinant adenoviral vector construction
To clone human endostatin, total RNA was extracted from human liver tissue (TRIzol; Invitrogen, Carlsbad, CA). The full-length human endostatin cDNA (about 570 bp) was amplified by RT-PCR using the primer (5 0 -CGGGATCCACAGCCACCGCGACTTCCAGCC-3 0 and 5 0 -GCGGATCCTACTTGGAGGCAGTCATGAA GC-3 0 ) with a BamHI restriction site in both primers (Titan One Tube RT-PCR kit; Roche, Mannheim, Germany). After sequence confirmation, the cDNA was cloned into a shuttle vector for the rescue of the recombinant E1-/E3-deleted adenovirus (AdEasy system) as described earlier. 30 The viral particles were amplified in 293 cells, purified by two-step cesium chloride gradient ultracentrifugation and measured by absorption (A260). The virus titer was quantified using a standard TCID50 assay. The recombinant Green Fluorescent Protein adenoviral (Ad-GFP) (replication-defective adenovirus type 5) was obtained.
Preparation of adenovirus vector complexed with PEG-PE cationic liposome Pegylated liposome was prepared as follows. Briefly, DOTAP, 1,2-dioleoyl-3-phosphatidylethanolamine, and PEG-PE were mixed at a molar ratio of 1:1:0.01 in chloroform. The mixture was evaporated at 40 1C in a rotary evaporator to remove the organic solvents. The dried lipid film was hydrated with 5% dextrose dissolved in distilled water. After incubation for 30 min at room temperature or overnight at 4 1C, the liposome solution was extruded. The extrusion step was repeated until liposomes showing 100-150 nm mean particle size with homogeneous particle size distribution were obtained. The particle size was measured by dynamic laser scattering using a MALVERN nano-zs particle sizer. The resulting Ad-liposome complexes were prepared fresh at room temperature.
Optimization of PEG-PE liposome and Ad vector ratio SKOV-3 cells were transfected with different PEG-PE liposome and Ad-GFP ratios. In brief, Cells were seeded into 6-well plates at a density of 2 Â 10 5 cells per well and used at 70-80% confluence. Varying amounts of liposomes (2, 5, 10, 15, 20 mg, respectively) were incubated with a fixed amount of Ad-GFP for 30 min at room temperature, and then added to SKOV-3 cells (500 p.f.u. per cell). At 48 h after infection, the percentage of GFP expressing was determined by FACS analysis.
Electron microscopy of Ad-Liposome complexes
The Ad-liposome complexes were visualized under an electron microscope by using a negative stain. Briefly, samples were applied to a Ni-filmed grid to which 3% neutral phosphotungstic acid was then applied. After being air dried, the stain was examined in a Hitachi H7650 transmission electron microscope at 80 kV. The particle diameter was analyzed using a particle size analyzer (Mastersizer 2000, USA).
Effect of neutralizing the antibody in vitro for SKOV-3 cells Rabbits were immunized with 10 9 p.f.u. of Ad-null by subcutaneous injection once per week for 4 weeks. Eight days after the fourth Ad injection, the rabbits were killed, and the neutralizing activity in blood from rabbits treated with Ad was assayed with SKOV-3 cells. Cells (2 Â 10 5 SKOV-3) were seeded in 6-well plates. The following day, serum was diluted 10-50 fold with RPMI-1640. According to the optimized ratio, complexes of Ad-GFP and PEG-PE cationic liposomes were used to infect SKOV-3 cells with or without the existence of the serum containing a neutralizing antibody at 37 1C for 30 min. In brief, cells were washed with phosphate-buffered saline, and the Enhanced antitumor effects via PEG-PE/Ad-hEndo L Yang et al mixture was added to SKOV-3 cells. After a 4-h incubation in a 5% CO 2 incubator at 37 1C, cells were washed with phosphate-buffered saline to remove the complexes and 2 ml fresh medium with 10% FBS was added. Cells were then incubated for an additional 48 h before assessing a GFP expression. The expression of GFP in infected cell samples were visualized with an Olympus microscope at Â 200 magnification.
Western blot analysis SKOV-3 cells were transfected with the complexes (PEG-PE cationic liposome and Ad-hEndo), Ad-hEndo and control adenovirus (Ad-null), respectively. Cells were conditioned at 37 1C for 48 h, and the supernatant was harvested and concentrated by ultrafiltration (Centricon YM-3; Millipore, Bedford, MA), and analyzed by western blot. Samples (10 ml) were separated on a 12% SDS-PAGE gel and transblotted onto a PVDF membrane. The membrane was blocked by TTBS (including 0.1% Tween 20 in TBS) with 5% non-fat milk and later it was probed with rabbit polyclonal anti-endostatin antibody (Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:500 at 4 1C overnight. Blots were then incubated with 1:5000 horseradish peroxidase-conjugated anti-rabbit immunoglobulins (Sigma, St Louis, MO). Protein bands were detected by ECL detection kit (GE).
Animal models and in vivo effects of Ad-hEndo/Lipo
Human ovarian serous cystocarcinoma SKOV-3 cells 1.0 Â 10 7 were injected into nude mice subcutaneously (s.c.) in 100 ml phosphate-buffered saline in the right flank. Seven days later, when the tumors were palpable, mice were randomly divided into four groups: (1) Ad-hEndo plus liposome group (Ad-E/Lipo), i.v. administration of 1 Â 10 8 p.f.u. recombinant adenovirus plus 20 mg liposome; (2) Ad-hEndo group (Ad-E), i.v. administration of 1 Â 10 8 p.f.u. recombinant adenovirus; (3) Ad-null plus liposome group (Ad-null/Lipo), i.v. administration of 1 Â 10 8 p.f.u. plus 20 mg liposome; and (4) normal saline (ns) group. To observe therapeutic effects, all of the treatments were performed once. Tumor growth was monitored by periodic caliper measurements every 7 days. The tumor volume ¼ 0.52 Â L Â W 2 , where W is the width of the tumor and L is the length of the tumor.
To observe survival time, mice were inoculated in the same way as above (n ¼ 10 per group) and treated once per week for 6 weeks; residual mice in all groups were killed 90 days after tumor establishment.
Immunohistochemical analysis and TUNEL assay
To determine the effect of anti-angiogenesis treatment on vessel density and apoptosis, frozen tissues were sectioned (5 mm) and fixed in acetone at 4 1C. Sections were probed with a monoclonal anti-CD31 antibody. Then, the sections were visualized and microvessels were calculated with an Olympus microscope at Â 200 magnification.
Apoptosis cells were identified through a TUNEL assay (In Situ Cell Death Detection Kit; Roche) following the manufacturer's guide. Images were captured by a fluorescence microscope. The blood vessels or the apoptosis cells were counted from five areas in each section in a blinded manner.
Statistics
The results of the statistical analyses are presented as means±s.d. For comparison of individual time points, differences between the groups were tested by performing ANOVA and an unpaired Student's t-test. Survival data were plotted on a Kaplan-Meier curve. All P-values were two-sided and statistical significance was defined as Po0.05.
Results

Encapsulation of PEG-PE cationic liposome enhances transfection efficiency of Adenovirus in vitro
The complex with PEG-PE liposome and Ad was verified by a transmission electron microscope (Figure 1 ). The size of the complexes was between 100-150 nm and the adenoviral particles were evenly distributed within the PEG-PE liposome.
The recombined adenovirus-encoding GFP were generated to detect transfection efficiency for SKOV3 cells. We tried to use fixed amounts of Ad-GFP to incubate with varying concentrations of PEG-PE liposomes and then infected SKOV-3 cells, which were CAR-deficient cells. 14 We found that Ad-GFP encapsulated with PEG-PE liposome shows increased transfection ability in SKOV-3. GFP expression increased and then reached a peak with increasing concentrations of PEG-PE liposome within 10 mg. However, Ad-GFP expression was decreased with increasing concentrations of PEG-PE liposome (15, 20 mg, respectively) (Figure 2a) . On the basis of these data, we selected liposome: Ad-GFP ratios of 10 mg:5 Â 10 7 vp, for further studies. Then, we used PEG-PE liposome-encapsulated Ad-GFP at the ratio of 10 mg:5 Â 10 7 vp to infect SKOV-3 cells with the existence of Ad-neutralizing antibody. However, the pre-existing neutralizing antibody failed to block the PEG-PE liposome-encapsulated Ad-GFP infection to SKOV-3 cells (Figures 2b-d) . This indicated that the PEG-PE liposome-encapsulated Ad-GFP can infect CAR-negative cells in a CAR-independent way.
Then, we investigated whether this system could offer a more efficient in vitro gene transfer to human ovarian cell lines than Ad-hEndo alone. We used the liposome-encapsulated Ad-hEndo to transfect SKOV-3 cells. Secretive endostatin protein was identified by western blot. A distinct band of about 20 kDa, corresponding to the size of endostatin, especially for the liposome-encapsulated Ad-hEndo, more light, more distinct, was visualized in the Ad-hEndo-treated cells, but not in Ad-null-transduced and Ad-hEndo-transduced cells (Figure 2e ).
Encapsulation of PEG-PE cationic liposome enhances antitumor effects of Ad-hEndo in vivo
In this study, the SKOV-3 subcutaneous xenograft model was used to analyze the therapeutic potential of Enhanced antitumor effects via PEG-PE/Ad-hEndo L Yang et al Ad-hEndo/Lipo. We first investigated whether PEG-PE liposome can synergize with endostatin to improve the antitumor effect by tail vein injection. To explore the feasibility of the approach, when small palpable tumor nodules could be easily seen under the skin after approximately 7 days, a single injection of complexes (1 Â 10 8 p.f.u. of Ad-hEndo plus 20 mg liposome) was administered intravenously at 7 days after tumor implantation. The mice had to be killed and the tumors were taken out to weigh, to undergo staining 49 days after tumor cell implantation due to excessive tumor volumes. The result showed that the treatment with Ad-hEndo/ Lipo resulted in a significant regression of established tumors compared with ns treatment, Ad-null/Lipo and Ad-hEndo treatment, respectively (Po0.05, Figure 3a) . Single injection of Ad-hEndo, Ad-null plus liposome or liposome caused reduction of tumor volume 34.58, 49.79 and 48.53%, respectively, whereas treatment with the complexes caused a very significant tumor volume reduction of 65.30%. On day 42 after virus vector injection, tumor growth was significantly reduced with the complex; the other treatment group did not inhibit such tumor growth. These results indicate that AdhEndo/Lipo produces an increased inhibition of tumor growth in vivo.
As the single injection with the complex appeared to be more effective than endostatin alone, the usefulness of this system for repeated administration of Ad vector was concerned, and the antitumor effect with repeated administration of complex in vivo was carried out. Sixtime intravenous injections were performed. In all cases, the cause of death was tumor progression or exhausted because of the tumor burden. Survival time with the complex treatment group was significantly longer than with other groups including the Ad-hEndo group. Although PEG contributes to extending the blood circulation time of adenoviral vectors and thus reduces the need for repeated administration, 31 the survival benefits may depend on the repeated administration of Ad-hEndo/Lipo.
Effective angiogenesis inhibition and increased apoptosis through Ad-hEndo/Lipo
To evaluate the consequence of anti-angiogenesis therapy, frozen tumor sections were stained with an endothelial-specific antibody against CD31. The microvessel density was counted. The decreased micro-vessel densities were found in Ad-hEndo/Lipo-treated tumors (Figure 4 ). 
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Apoptotic cells in tumors were determined by TUNEL assay. The liposome group was found to induce low levels of apoptotic cells in the tumor region, whereas the number of apoptotic cells in the Ad-hEndo/Lipo-treated group was significantly higher than that of other groups. More importantly, the complex with adenoviral and liposome further increased the number of apoptotic cells compared with the Ad-hEndo (Po0.001) alone ( Figure 5 ).
Encapsulation with PEG-PE cationic liposome of Ad-hEndo impairs the anti-Ad antibody response
For detection of anti-Ad antibody response of PEG-PE cationic liposome of Ad-hEndo, we performed repeated intravenous injections of Ad-null/Lipo, Ad-hEndo or AdhEndo/Lipo in immunocompetent Balb/c mice. Ten days after the first injection, we measured the levels of anti-Ad antibody in the serum of treated wild Balb/c mice. The anti-Ad IgG level of mice receiving three intravenous injections of Ad-hEndo/Lipo or Ad-null/Lipo was significantly lower than that of mice receiving three intravenous injections of Ad-hEndo (Figure 6a ). This result suggests the availability of repeated and systemic administration with Ad-null/Lipo to effectively inhibit angiogenesis.
Toxicity observation
To evaluate the health status of mice treated with Adnull/Lipo injection, the weight of mice was monitored once every 3 days throughout the whole experiment and considered a parameter for evaluation of systemic wellbeing, anorexia or cachexia. No significant differences in weights were found among all the groups (Figure 6b) . No adverse effects in other gross measures, such as skin ulcerations or toxic death, were observed in the Ad-null/ Lipo group. Furthermore, toxic pathological changes in the liver, lungs, kidneys, spleen, brain or heart were not detected by microscopic examination.
Discussion
Almost all the ovarian cancer adenoviral gene therapy trials published have relied on the intraperitoneal administration of the vector because ovarian cancer patients often present with malignant ascites and those gene products mainly generate direct cytotoxicity to ovarian cancer cells. [32] [33] [34] Endostatin-based gene therapy targets blood vessel-proliferating endothelial cells, but clinically, however, intravenous and prolonged administration is required for better benefits. Moreover, the intratumoral Enhanced antitumor effects via PEG-PE/Ad-hEndo L Yang et al high concentration of endostatin should contribute more to inhibit the proliferation of endothelial cells. There is a problem that the CAR levels are often low in primary ovarian and other tumor cells; 35 it is noted that CAR could not be detected in the endothelial cells of the vasculature. 36 Therefore, in this study, we performed a systemic and repeated administration with a PEG-PE cationic liposome-encapsulated adenovirus to explore the antitumor effects in a CAR-negative ovarian cancer model. Enhanced antitumor effects via PEG-PE/Ad-hEndo L Yang et al
Normally, the binding between adenovirus and targeting cells was dependent on an electrostatic interaction of the adenovirus fiber protein with the cell surface. Cationic liposome can bind to adenovirus and increase the efficiency of gene transfer in vitro and in vivo to various cells and tissues, and thus provides a preferable way to improve the ability of the vector to infect cancer cells. 27, 37, 38 Adenovirus with polycationic polymers and cationic lipids enter cells through a pathway different from that used by adenovirus alone. 39 Previous studies have shown that complex Ad vector with cationic liposomes can increase infection in CARdeficient cells. 28, 40, 41 In fact, previous investigations have further suggested that liposome complexes with The values constitute quantitative data in mixed sera from five mice. (b) Body weights of mice were plotted and the curve of the Ad-E/Lipo-treated group paralleled very closely to that of the control liposome and ns groups with no significant differences among them (P40.05).
Enhanced antitumor effects via PEG-PE/Ad-hEndo L Yang et al adenovirus prepared with DOTAP were relatively more stable than those DOTMA in vitro. 42 PEG incorporation into DOTAP liposome-enhanced stability and uptake of liposome-complexed adenoviral and further improved the infection efficiency regardless of infection conditions and reported that in CAR-deficient cells. In this study, we prepared PEG-PE cationic liposome to encapsulate adenovirus and confirmed that the resulting complex could enhance the transfection ability both in vitro and in vivo. Secretory endostatin protein was detected in supernatant from Ad-hEndo/ Lipo-treated cells with the same ration regardless of negative CAR expression in SKOV-3 cells. In vivo, AdhEndo/Lipo shows lasting inhibition to established SKOV-3 tumors indicating the prolonged expression of endostatin. These findings support that the gene therapy strategy of anti-angiogenesis based on PEG-PE cationic liposome is feasible for cancer therapy, regardless of CAR expression.
However, there is another problem that neutralizing antibodies which could inactivate adenovirus vector result in failure to repeated administrations of adenovirus recombinant. It is reported that mice subcutaneously injected with liposome-conjugated Ad vector showed a 6.5-fold reduction of anti-Ad antibodies with neutralizing activity, compared with those with unconjugated Ad vector. 43 In our study, however, the anti-adenovirus IgG levels from complex-injected mice were about 12-fold lower than those from Ad-hEndo injected alone. The PEG-PE cationic liposome system shows better protective activity from host immune clearance; this suggests that Ad-hEndo/Lipo can escape from host immunity and thus possibly be repeatedly applied through intravenous administration. Although these results show that antiangiogenesis therapy results in reduced tumor angiogenesis leading to apoptotic death of ovarian cancer cells, regretfully, it is also important to note that the complex was unable to inhibit tumor growth fully. It is necessary to optimize liposomal formations and therapeutic schema to obtain better therapeutic efficacy.
In summary, our studies show that Ad can be encapsulated by PEG-PE liposome. Adenovirus-mediated anti-angiogenesis gene therapy based on PEG-PE liposome can be used to inhibit the growth of ovarian cancer and liposome can synergize with endostatin. Our findings may have significant implications for enhancing clinical outcomes in adenoviral cancer gene therapy and, more importantly, for the development of more efficient vectors.
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